Purpose We previously identified small molecules that fit into a BRCA1-binding pocket within estrogen receptoralpha (ERa), mimic the ability of BRCA1 to inhibit ERa activity (''BRCA1-mimetics''), and overcome antiestrogen resistance. One such compound, the hydrochloride salt of NSC35446 (''NSC35446.HCl''), also inhibited the growth of antiestrogen-resistant LCC9 tumor xenografts. The purpose of this study was to investigate the down-stream effects of NSC35446.HCl and its mechanism of action.
BRCA1

Introduction
Although most studies on the breast cancer susceptibility gene BRCA1 have focused on its role in the maintenance of genomic integrity [1, 2] , BRCA1 also regulates estrogen receptor-alpha (ERa) activity [3] [4] [5] [6] [7] [8] [9] [10] and Tamoxifen sensitivity [8, 11, 12] . Thus, BRCA1 over-expression reverses Tamoxifen resistance in LCC9 cells [12] , which are antiestrogen resistant but express wild-type estrogen receptor-alpha (ERa) [13, 14] . BRCA1 inhibition of ERa is dependent upon an interaction between the amino-terminus of BRCA1 and the carboxyl-terminus of ERa [4, 5, 7] . Based upon high-resolution mapping studies, we created a three-dimensional model of the BRCA1:ERa interaction [with ERa ligated to 17b-estradiol (E2)] [7] . Using this model, a BRCA1-binding surface in ERa was found to contain two pockets suitable to accommodate small molecules [15] . We screened a pharmacophore database [National Cancer Institute/Developmental Therapeutics Program (NCI/DTP)] to identify small molecules that could fit into one of these pockets. We identified six compounds that inhibit ERa activity in both antiestrogensensitive/E2-responsive MCF-7 cells and antiestrogen-resistant LCC9 cells [15] . These compounds (''BRCA1-mimetics'') bind to ERa through a pocket distinct from the ligand-binding pocket and, thus, work differently from Tamoxifen and Fulvestrant, which bind to the ligandbinding pocket. The prototype compound, A7 (NSC31303), exhibited an IC 50 of 2-3 lm for inhibition of ERa. We created a second BRCA1:ERa interaction model, this time with ERa ligated to Tamoxifen. Based on a model of the BRCA1-binding pocket in ERa, we screened the same pharmacophore database and identified six different BRCA1-mimetic compounds [12] . These compounds inhibited ERa in MCF-7 cells (IC 50 B 1.0 lm), and four of the six exhibited similar activity in LCC9 cells. NSC35446 represents a prototype such compound. Unlike A7, these compounds partially restored sensitivity of LCC9 cells to Tamoxifen. A slightly modified form of NSC35446 (the hydrochloride salt, ''NSC35446.HCl'') significantly inhibited the growth of LCC9 tumor xenografts at non-toxic concentrations. Both sets of BRCA1-mimetic compounds appear to function by disrupting the interaction between ERa and the ERE.
Materials and methods
Cell lines and culture
Human breast cancer cells (LCC9, T47DCO, MCF-7, MCF-7/RR, LY2, MDA-MB-231, MDA-MB-468, and HCC1806) were obtained from the Lombardi Comprehensive Cancer Center Tissue Culture Shared Resource (TCSR). MCF-7, MD-MBA 231, and HCC1806 were grown in DMEM plus 5% fetal calf serum (FCS) (Lonza, Walkersville, MD). LCC9, MCF-7/RR, LY2, and T47DCO were grown in phenol red-free IMEM (Corning Cellgro, Manassas, VA) plus 5% charcoal-stripped serum (CSS) (TCSR). MDA-MB-468 cells were grown in RPMI 1640 (Corning Cellgro) plus 5% FCS.
Reagents
Trypan blue was purchased from Thermo Fisher Scientific (Waltham, MA). Compound A7 (NSC31303) was obtained from the NCI/DTP and dissolved in DMSO (Sigma-Aldrich, St. Louis, MO) [15] . NSC35446.HCl was synthesized as described earlier [12] and dissolved in DMSO. Cell-permeable caspase inhibitors were purchased in solution in DMSO from Millipore (Billerica, MA): InSolution TM Caspase Inhibitor I (pan-caspase inhibitor) (Z-VAD-FMK) and InSolution TM Caspase-8 Inhibitor II (selective CASP8 inhibitor) (Z-IETD-FMK). Fulvestrant was a gift from Dr. Robert Clarke (Department of Oncology, Georgetown University). 17b-Estradiol (E2) was purchased from Sigma-Aldrich and dissolved in ethanol.
Cell proliferation assays
Growth media for proliferation assays were the same as described above except using 1% CSS or 1% FCS. Subconfluent proliferating cells were seeded into 6-well dishes at 1 9 10 5 cells/well on Day 0 and allowed to attach for 24 h. The cells were treated with vehicle or NSC35446.HCl starting on Day 1, with daily re-feeding with fresh medium containing vehicle or compound. Trypan blue dye-excluding cells were counted in triplicate wells by hemocytometer on Days 1, 3, and 5. For experiments using caspase inhibitors, the cells were pre-incubated for 12 h with the indicated inhibitor(s) (10 lm).
Cell-cycle analysis
Subconfluent proliferating cells were seeded into 100-mm dishes at 6 9 10 5 cells/dish, allowed to attach for 24 h, and treated with vehicle or NSC35446.HCl for 48 h. The cells were then harvested using trypsin, fixed using 70% ethanol, and stained with propidium iodide (BD Biosciences, San Jose, CA). Samples were analyzed on a BD LSRFortessa TM Cell Analyzer. DNA histograms were analyzed using ModFit software (Verity Software House, Topsham, ME).
Mammosphere assays
Cells were treated with vehicle or NSC35446.HCl for five days, after which the cells were re-plated in six-well nonadherent dishes (Corning, NY) at 5 9 10 3 cells/well. Mammospheres/well or non-mammosphere aggregates/ well were counted after seven days with an inverted phase contrast microscope (Olympus IX-71), using a grid.
RNA-seq
Subconfluent proliferating LCC9 cells were treated with vehicle (DMSO) or A7 (5 lm) for 24 h and harvested for RNA extraction. Two independent experiments were performed. Total RNA was extracted using the miRNeasy Mini Kit (Qiagen, Valencia, CA) and submitted to Otogenetics Corporation (Norcross, GA) for RNA-seq analysis. After verifying the integrity and purity of total RNA, cDNA was generated using a SMARTer R PCR cDNA Synthesis Kit (Clontech Laboratories, Inc., Mountain View, CA). Reference measurements were composed of 21,366,072 total reads/sample for vehicle-treated control with 89.5% of RNA-seq reads mapped to the human genome and 21,619,802 total reads/sample for A7-treated cells with 87.4% of RNA-seq reads mapped to the human genome. The RNA-seq data were deposited in the Gene Expression Omnibus (GEO) database and can be accessed at https://www.ncbi.nlm.nih.gov/geo/ (accession number: GSE101691). Results were analyzed using Ingenuity Pathway Analysis software (Qiagen Bioinformatics, Redwood City, CA).
qRT-PCR
After the indicated cell treatments, RNA was extracted using the miRNeasy Mini Kit (Qiagen) and converted to cDNA using Taqman R Reverse Transcription Reagents (Applied Biosystems-Roche, Foster City, CA), using 3 lg of total cellular RNA. qRT-PCRs were carried out in a 25-lL reaction volume, containing 5 lL (5%) of cDNA, 12.5 lL of Power SYBR R Green PCR Master Mix (Applied Biosystems), 2.5 lL of nuclease-free water (Ambion-Life Thermo Fisher, Waltham, MA), and 5 lL (2 lg) of primers (IDT Technologies, Coralville, IA) (Supplementary Table S1 ). b-Actin was used as a loading control. The cycling conditions were as follows: denaturation at 95°C for 15 s and annealing/extension at 60°C for 1 min, for a total of 45 cycles.
Western blotting
Cells were seeded into 100-mm dishes (6 9 10 5 cells/dish), incubated for 24 h, and treated with vehicle or NSC35446.HCl for the indicated time before lysis in RIPA buffer. Equal aliquots of whole-cell protein (30 lg/lane) were electrophoresed on 4-20% SDS-polyacrylamide gradient gels, transferred to PVDF membranes (Millipore), and blotted overnight using primary antibodies listed in Supplementary Table S2 . The membranes were blotted for 1 h with the appropriate secondary antibody (1:5000; Santa Cruz Biotechnology, Santa Cruz, CA), and the blotted proteins were visualized with the ECL detection system (Denville Scientific, Hollistin, MA), with colored molecular size markers (Bio-Rad Laboratories, Hercules, CA). Densitometry was performed using ImageJ software (NIH).
Assays of NF-jB transcriptional activity
Subconfluent proliferating cells in 6-well dishes were transfected overnight with 1 lg of NF-jB reporter pGL3-NF-jB-luc or 1 lg of control plasmid pGL3-luc (gifts from Dr. Robert Clarke), and 1 lg of Renilla-luc plasmid (a gift from Dr. Rebecca Riggins, Department of Oncology, Georgetown University) in serum-free IMEM containing Lipofectamine R LTX (Life Technologies, Washington, DC). The cells were washed, incubated in IMEM containing 5% CSS, and treated with vehicle or NSC35446.HCl (5 lm) for 48 h. Lysates were analyzed using the Dual-Luciferase R Reporter Assay (Promega). Luciferase activity was normalized to the Renilla signal. Each assay condition was tested in quadruplicate.
TUNEL assays
Cells were seeded into 100-mm dishes (6 9 10 5 cells/dish), incubated for 24 h, and treated with vehicle or NSC35446.HCl for 48 h. TUNEL assays were performed using an APO-BRDU TM Kit (BD Biosciences). After treatment, the cells were counted and the volume equivalent of 5 9 10 5 cells was fixed with paraformaldehyde/ ethanol. Fixed cells were treated with TdT enzyme and BrdUTP, stained with an FITC-labeled anti-BrdU monoclonal antibody, and incubated for 60 min at 37°C. The cells were washed, re-suspended, and analyzed to detect FITClabeled fragmented DNA by flow cytometry. DNA histograms were analyzed using ModFit software.
Annotating putative ERE half-sites and ERE-like full-sites in the IKKB promoter R packages (R project free software environment for statistical computing and graphics) for genomic coordinate and sequence manipulation were used to extract sequence corresponding to the promoter region of IKKB gene to 10,000 bp upstream of the transcription start site (TSS). Genomic sequence for this region was extracted using the BSgenome and BSgenome.HsapiensUCSC.hg19 R packages. Pattern matching was performed on the extracted sequence using the Biostrings package, looking for estrogen response element (ERE) half-sites ''TGACC'' or ''GGTCA'' with no mismatches or for ''GGTCANNNT-GACC'' (N = any nucleotide) with up to two mismatches, permitting indels (insertion or deletion of nucleotides). The discovered coordinates were annotated for ChIP verification. Supplementary Table S3 contains a listing of the nine ERE half-sites and one ERE-like full-site (with one nucleotide mismatch) within the IKKB promoter. One such half-site ERE (TGACC half-site 1) was adjacent to an Sp1 site (Sp1/ERE half-site).
Chromatin immunoprecipitation (ChIP) assays
Subconfluent proliferating LCC9 or T47DCO cells were seeded into 100-mm dishes (6 9 10 5 cells/dish), incubated for 24 h, and treated with vehicle or NSC35446.HCl as indicated. ChIP assays were performed using two commercial kits, the truChIP TM Chromatin Shearing Reagent Kit (Covaris, Woburn, MA), and the Magna ChIP TM HiSens Chromatin Immunoprecipitation Kit (Millipore). DNA-protein cross-linking was carried out by addition of 11.1% formaldehyde and incubation for 5 min @ 25°C. Cells were lysed by addition of Lysis Buffer A. The lysates were sonicated @ 6°C, and the concentration of sheared DNA was measured by NanoDrop. Four lg of ERa antibody (AER304, mouse monoclonal, Millipore) or mouse non-immune IgG (Millipore) was utilized for IPs. The DNA was incubated with protein A/G magnetic beads (Millipore) for pre-linking @ 4°C for 2 h. Five percent of undiluted DNA was set aside as input. DNA corresponding to 7 9 10 5 cells was incubated with the beads at 4°C overnight. Beads were washed with low stringency IP wash buffer. The DNA was eluted by overnight treatment with Proteinase K and RNase H at 57°C. It was then purified and subjected to qPCR amplification of sequences surrounding the previously identified EREs of the IKKB promoter or the known ERE of the pS2/TFF1 promoter [16] (Supplementary Table S3 ). Primers were obtained from IDT Technologies. Thermal cycling conditions were as follows: denaturation at 95°C for 15 s annealing/extension at 60°C for 1 min, for a total of 45 cycles.
In some experiments, MCF-7 cells were treated ± E2 (10 nM) and ± Fulvestrant (1 lM) for 120 min and assayed to detect ERa at the known EREs of the pS2 or GREB1 [17] promoters. In other experiments, MCF-7 cells were exposed to E2 for 120 min, then treated with vehicle or NSC35446.HCl for 48 h, and then and assayed to quantify ERa at the pS2 or GREB1 EREs.
Statistical analysis
All values are reported as means ± SEMs of three or four independent experiments. Statistics were calculated using the two-tailed t test, with p \ 0.05 being considered significant. Statistical significance was analyzed using GraphPad Prism 6 software (GraphPad Software, La Jolla, CA).
Results
NSC35446.HCl inhibits cell proliferation in antiestrogen-resistant cells
NSC35446.HCl (Fig. 1a) inhibited proliferation in antiestrogen-resistant LCC9 and T47DCO cells but not in ERa-negative MDA-MB-231, HCC1806, and MDA-MB-468 cells (Fig. 1b and data not shown) . A higher concentration of NSC35446.HCl was used for T47DCO (10 lm) than for LCC9 (5 lm) because T47DCO cells were slightly less sensitive to the compound than LCC9. Inhibition of LCC9 proliferation was concentration-dependent, with about half-maximal inhibition observed at 0.3 lm of compound ( Supplementary Fig. S1a ). The compound also inhibited the proliferation of two MCF-7-derived ERa-positive antiestrogen-resistant cell lines, MCF-7/RR and LY2 (Supplementary Fig. S1b ). Compound did not alter the LCC9 cell-cycle distribution, but there was a significant sub-G1 population in the compound-treated cells, consistent with apoptosis (Fig. 1c) .
NSC35446.HCl also caused dose-dependent inhibition of LCC9 mammosphere formation, whereas formation of mammospheres and non-mammosphere aggregates by MDA-MB-231 was unaffected ( Fig. 1d; Supplementary  Fig. S1c) . Thus, the compound may target mammosphereforming capacity of LCC9 cells, which correlates with the number of cancer stem cells.
RNA-seq analysis of LCC9 cells treated with BRCA1-mimetic
We initially evaluated the effects of A7 (NSC31303) (Fig. 2a) on gene expression through RNA-seq. We identified a large set of genes differentially expressed in A7-treated compared with vehicle-treated cells (data not shown). A selected set of eight genes that were up-or down-regulated by A7 (Supplementary Table S4) were validated using qRT-PCR (Fig. 2b) . All eight genes were altered in the same direction as in the RNA-seq experiment. We next tested the ability of NSC35446.HCl to alter expression of this gene set and found that seven of eight genes (all except MAP3K7) were regulated in the same direction by NSC35446.HCl and A7 (Fig. 2c) . Both A7 and NSC35446.HCl down-regulated expression of pS2, a known ERa-responsive gene. Since IKKB mRNA expression was down-regulated by A7 and NSC35446.HCl, we tested the effect of the compounds on IKKA and IKKG mRNA expression in LCC9 cells. Both IKKA and IKKG expressions were significantly down-regulated by A7 and NSC35446.HCl starting after 6-24 h of compound treatment (Fig. 2d, e) . Note that, IKKA and IKKG mRNA were down-regulated in the RNA-seq experiment, but, unlike IKKB, the P values were not significant.
Pathway Studio Analysis of RNA-seq data revealed differential expression around the NF-jB pathway (Supplementary Fig. S2a) , consistent with down-regulation of IKKB shown in both validations. The heat map in Supplementary  Fig. S2b shows the effect of compound A7 on genes that can influence the NF-jB complex or IKKB (IKBKB). We selected IKKB and NF-jB signaling for further study. These studies were performed using NSC35446.HCl because this compound was more potent than A7.
NSC35446.HCl reduces expression of IKK proteins in antiestrogen-resistant cells
We tested the effect of NSC35446.HCl on expression of IKKB and other IKK proteins in LCC9 cells. Western blotting revealed that NSC35446.HCl caused a non-significant effect at 24 h ( Fig. 3a; Supplementary Fig. S3a ) and a significant decrease of IKKB, IKKA, IKKG protein in LCC9 cells at 48 and 72 h (Fig. 3b, c; Supplementary  Figs. S3b, c) . As a positive control, NSC35446.HCl caused significant decreases in pS2 protein at 24, 48, and 72 h ( Fig. 3; Supplementary Fig. S3d ). The compound-induced down-regulation of IKK protein expression was concentration-dependent ( Supplementary Fig. S4 ). Like LCC9, NSC35446.HCl also significantly down-regulated IKKB, IKKA, and IKKG protein levels in antiestrogen-resistant MCF-7/RR and LY2 cells (Supplementary Fig. S5 ).
The effect of the compound on IKKB mRNA was quantified by qRT-PCR. Down-regulation of IKKB mRNA expression in LCC9 cells was both concentration-and Fig. 3d; Supplementary Fig. S6a ). At a concentration of 5 lm of compound, a reduction in IKKB mRNA preceded that of the protein. Inhibition of IKKB mRNA by compound was also observed in MCF-7/RR and LY2 cells (Supplementary Fig. S6b ).
NSC35446.HCl inhibits NF-jB transcriptional activity in antiestrogen-resistant cells
Because NF-jB stimulates expression of anti-apoptotic genes [18] , we investigated whether NSC35446.HCl alters NF-jB activity, using the reporter pGL3-NF-jB-luc and control plasmid pGL3-luc. NF-jB activity in LCC9 cells was significantly decreased by a 48-h exposure to NSC35446.HCl; however, NSC35446.HCl did not reduce NF-jB activity in ERa-negative MDA-MB-231 cells (Fig. 4a) . As before, the NSC35446.HCl inhibition of NFjB was concentration dependent, with about 50% inhibition at 0.3 lm (Supplementary Fig. S7 ).
We next examined the effects of the compound on protein levels of several NF-jB-regulated genes. Western blotting showed a significant decrease in the levels of antiapoptotic proteins CIAP1, TRAF2, BCL2, and BCLXL in LCC9 and T47DCO cells ( Fig. 4b; Supplementary  Figs. S8a, b) . NSC35446.HCl also caused a significant increase of IRF1 protein in LCC9 and T47DCO cells ( Fig. 4c; Supplementary Figs. S8a, b) . IRF1, an NF-jBregulated gene [19] , is a tumor suppressor that induces apoptosis [20, 21] . The ability of the compound to inhibit NF-jB-regulated anti-apoptotic protein expression was also concentration dependent, as illustrated in Supplementary Fig. S9 .
NSC35446.HCl causes caspase-dependent apoptosis in antiestrogen-resistant cells
LCC9 cells lack caspase-3, so we tested the ability of NSC35446.HCl to cause CASP7 cleavage. Although NSC35446.HCl did not cause a reduction in uncleaved CASP7, it caused a significant increase in cleaved CASP7 ( Fig. 5a; Supplementary Fig. S10a ). Treatment with a pancaspase inhibitor, a CASP8 inhibitor, or both blocked inhibition of cell proliferation due to NSC35446.HCl (Fig. 5b) . Another Western blot study revealed that a combination of caspase inhibitor(s) with compound blocked the increase in cleaved CASP7 due to compound ( Fig. 5c; Supplementary Fig. S10b ). Western blotting was also performed for CASP8, but no CASP8 was detected (data not shown). Unlike LCC9, NSC35446.HCl did not cause down-regulation of IKKB protein or CASP7 cleavage in ERa-negative cell lines MDA-MB-468 and HCC1806 ( Supplementary Fig. S11 ). Next, we tested the effect of a 48-h treatment with compound on apoptosis using a TUNEL assay. This assay revealed less than 10% apoptosis in vehicle-treated cells but a large apoptotic fraction (ca. 50%) in compound-treated LCC9 cells (Fig. 5d) . Compound-induced apoptosis was concentration dependent ( Supplementary  Fig.  S12 ). Finally, NSC35446.HCl caused apoptosis in T47DCO cells but not in MDA-MB-231 or HCC1806 cells ( Supplementary  Fig. S13 ). These data are consistent with the proliferation and cell-cycle data.
NSC35446.HCl inhibits ERa recruitment to the IKKB promoter
Since the IKKB gene is not known to be estrogen-regulated, we performed an in silico analysis to identify putative b Western blotting of NF-jB-responsive genes was performed after a 48-h treatment with vehicle or NSC35446.HCl (5 lm). Data are shown for three or four independent experiments. c Western blotting for IRF1 was performed after a 48-h treatment with vehicle or NSC35446.HCl (5 lm). Results of four independent experiments are shown. *p \ 0.05, **p \ 0.01, ***p \ 0.001, ns not significant EREs in its promoter. We identified one ERE-like full-site (with one nucleotide mismatch) and nine ERE half-sites (Supplementary Table S3 ). We performed ChIP assays to quantify ERa accumulation in a segment of DNA surrounding each ERE. For the ERE-like full-site, we utilized two different PCR amplicons. Non-immune IgG IP of vehicle-treated cells was used as a negative control. NSC35446.HCl inhibited ERa recruitment to the ERE-like full-site and five of the nine half-sites in LCC9 cells (Fig. 6a, b) . Inhibition of ERa recruitment to the ERE-like full-site by compound was concentration-dependent and was significant at concentrations as low as 0.3 lm of compound ( Supplementary Fig. S14a ). Inhibition of ERa recruitment was observed as early as 12 to 24 h, depending on the ERE site tested (Supplementary Fig. S14b, c) . Four of the nine half-sites showed no significant amplified product. Similarly, a non-ERE site 15 kbp upstream of the TSS showed no significant ERa recruitment (Supplementary Fig. S15 ). NSC35446.HCl also blocked the ERa signal from the pS2 ERE and from the IKKB ERE-like full-site in T47DCO cells (Supplementary Fig. S16a) .
As another control, we tested the ability of Fulvestrant, which causes ERa degradation [22, 23] , to inhibit the E2-stimulated ERa recruitment to the EREs of the pS2 and GREB1 genes in antiestrogen-sensitive/E2-responsive MCF-7 cells (Supplementary Fig. S16b ). E2 caused ERa HCl for 48 h. Whole-cell lysates were analyzed by Western blotting for uncleaved and cleaved CASP7. Four independent experiments are shown. b Cells were treated ± the indicated caspase inhibitor(s) (10 lm) and ± NSC35446.HCl (5 lm), and growth curves were performed. Curves are means ± SEMs of three independent experiments. c Experiments were performed as in (a), except that cells were treated with caspase inhibitors ± NSC35446.HCl. The Western blot shown is representative of three independent experiments. d Cells were treated daily with vehicle or NSC35446.HCl (5 lm) for 48 h, after which a TUNEL assay was performed using the APO-BRDU TM Kit (BD Biosciences) and flow cytometry to detect FITC-labeled apoptotic fragmented DNA. The histogram shown is representative of three independent experiments. The ordinate represents cell count, and the abscissa represents the FITC label. Values plotted are means ± SEMs of three independent experiments. *p \ 0.05, **p \ 0.01, ***p \ 0.001 accumulation at these EREs, while co-treatment with Fulvestrant inhibited the E2-stimulated ERa accumulation. And NSC35446.HCl blocked the subsequent E2-stimulated ERa recruitment to the EREs of pS2 and GREB1 in MCF-7 cells (Supplementary Fig. S16c ).
We performed Western blotting to rule out the possibility that loss of ERa occupancy at IKKB ERE sites due to NSC35446.HCl is caused by a decrease in ERa protein levels. There was no change in ERa levels due to a 48-h treatment with compound ( Supplementary Fig. S17 ). In contrast, the compound significantly reduced the pS2 levels.
Discussion
The ability of NSC35466.HCl to inhibit NF-jB signaling may, in part, explain its ability to cell proliferation and cell survival in antiestrogen-resistant LCC9 cells (resistant to Tamoxifen and Fulvestrant), which are MCF-7-derived (13) . NSC35466.HCl also inhibited proliferation in two other ERa-positive MCF-7-derived antiestrogen-resistant cell lines, MCF-7/RR (resistant to Tamoxifen) and LY2 (resistant to antiestrogen LY 117018) [24, 25] . And NSC35466.HCl blocked proliferation and induced apoptosis in T47DCO cells and blocked their expression of NFjB-regulated genes. T47DCO cells are antiestrogen resistant and express a mutant form of ERa [26] . In contrast, NSC35466.HCl does not inhibit cell proliferation or NFjB signaling in ERa-negative MDA-MB-231, HCC1806, or MDA-MB-468 cells and does not cause down-regulation of IKKB protein in MDA-MB-468 or HCC1806 cells. Consistent with the idea that NF-jB regulates LCC9 resistance to antiestrogens, it has been shown that Parthenolide (a selective inhibitor of NF-jB transcriptional activity) or over-expression of a dominant-negative mutant IjB restored sensitivity of LCC9 cells to antiestrogens Fulvestrant and Tamoxifen [27, 28] . This effect could be reversed by a CASP8-specific inhibitor. The latter is consistent with our finding that a CASP8-specific inhibitor blocked the ability of NSC35466.HCl to inhibit LCC9 cell proliferation and cause CASP7 cleavage.
It has been established previously that E2 and other ERa ligands (though not Raloxifene, a selective estrogen receptor modulator like Tamoxifen) can inhibit NF-jB activity [29] [30] [31] , although in some contexts E2 can stimulate NF-jB activity by a non-genomic action [32] . It has also been found that the ability of ERa to mediate transactivation due to E2 or other ligands can be dissociated from its ability to mediate suppression of NF-jB transcriptional activity [29, 30] . Interestingly, BRCA1 itself has been found to stimulate NF-jB-mediated transcription by binding directly to the p65/RelA subunit although this effect could be demonstrated in both ERa-positive and ERa-negative cells [33] . Our findings suggest that an ERa transcriptional antagonist, NSC35446.HCl, can also suppress NF-jB activity and that the mechanism may, in part, involve targeting its upstream activator IKKB.
Interferon-c, an inflammatory cytokine that induces expression of interferon regulatory factor-1 (IRF1), induces IRF1 expression in LCC9 cells, restores sensitivity to Fulvestrant, inhibits NF-jB activity, inhibits anti-apoptotic gene expression, and stimulates pro-apoptotic genes expression [34] . IRF1 is down-regulated in LCC9, as compared with MCF-7 cells, while NF-jB activity is upregulated in LCC9 [35] . These findings are consistent with the idea that IRF1 induces antiestrogen sensitivity in LCC9 cells [35] and are consistent with our finding that NSC35446.HCl up-regulates IRF1 protein expression in LCC9 and T47DCO cells.
Our in silico analysis revealed one imperfect full-site ERE (with one nucleotide mismatch) and nine perfect halfsites, including one Sp1/ERE site (TGACC half-site 1), in the IKKB promoter. ChIP assays revealed that the imperfect full-site and five of the nine half-sites (including TGACC half-site 1) showed measurable ERa accumulation that was significantly reduced by NSC35446.HCl in LCC9 and T47DCO cells. We are unaware of any prior reports of ERE sites within the IKKB promoter or E2/ERa-sensitivity of the IKKB gene. However, several reports suggest that ERE half-sites in other genes can strongly bind ERa and are functional [36] [37] [38] [39] [40] [41] [42] [43] [44] . This includes Sp1/ERE half-sites, which can bind a ternary Sp1-ERa-DNA complex [36, 40, 42, 44] . In our study, the greatest quantitative accumulation of ERa in vehicle-treated LCC9 cells occurred at the Sp1/ERE half-site. ERa is also known to bind to imperfect full-site EREs [45, 46] . Even the known full-site ERE of the pS2 promoter shows a one nucleotide mismatch relative to the canonical ERE sequence [16] . The quantitative magnitude of ERa accumulation at the imperfect ERE full-site and the five ERE half-sites of the IKKB promoter was similar in vehicle-treated LCC9 cells as was E2-induced ERa accumulation at the known pS2 and GREB1 EREs in MCF-7 cells, suggesting that these IKKB sites are functional.
Our previous studies [12, 15] may shed some light on the mechanism by which our compound reduces ERa occupancy at the IKKB EREs. Thus, electrophoretic mobility shift and supershift assays revealed that a 24-h pre-incubation of BRCA1-mimetic compounds with intact MCF-7 cells caused dissociation of the E2-induced complex of ERa and a consensus ERE oligonucleotide. If, instead of pre-incubation, NSC35446 (the free-base form of NSC35446.HCl) was added directly to the nuclear extract reaction mixture with ERE oligonucleotide, dissociation of the E2-induced ERa:ERE complex was observed at a much lower concentration of compound [12] . These findings suggest that the intact cell presents a barrier to the interaction of compound with ERa and are consistent with a model in which a direct interaction of ERa with the compound causes a conformational change of ERa that results in dissociation of the ERa:ERE complex or prevents formation of the complex. This is analogous to the way ligation of E2 to ERa promotes a profound conformational change that allows recruitment of ERa to the ERE or the way ligation of Tamoxifen to ERa also causes a profound conformational change, even though E2 and Tamoxifen bind to the ligand-binding pocket in the C-terminus of the protein. It is noted that our compounds bind to a site near the ligand-binding pocket (between the ligand-binding pocket and the coactivator ridge) but not at the pocket [12, 15] .
NSC35446.HCl down-regulated the mRNA and protein expression of three IKK isoforms, IKKB, IKKA, and IKKG/NEMO, in antiestrogen-resistant LCC9 cells but did not down-regulate protein expression of IKKB in ERanegative MDA-MB-468 or HCC1806 cells. Thus, other genes within the NF-jB signaling pathway may be targeted by our compound in LCC9 cells. Interestingly, IKKG was shown to be a component of a signaling network that impinges on the key nodes of NF-jB, IRF1, and X-box binding protein-1 (XBP1) and regulates the antiestrogen sensitivity of LCC9 cells [47] . Our findings suggest that components of this same network may be involved in regulation of the response to NSC35446.HCl.
In LCC9, cell proliferation, mammosphere formation, IKK protein expression, IKKB mRNA expression, NF-jB activity, NF-jB-dependent anti-apoptotic protein expression, apoptosis, and ERa occupancy at the IKKB promoter were all dependent on the concentration of compound NSC35446.HCl. While none of these parameters were affected by a concentration of 0.01 lm, all were significantly inhibited at 0.3 lm or more of compound. For some parameters, approximately half-maximal effects were observed at the 0.3 lm concentration.
A recent study indicates that pro-inflammatory cytokines can induce antiestrogen resistance in MCF-7 cells that is dependent on phosphorylation of ERa at S305 [48] . This phosphorylation, which causes a conformational change in ERa that induces antiestrogen resistance in MCF-7 cells, is mediated by IKKB. This finding suggests that IKKB is a target for endocrine resistance in MCF-7 cells, by a mechanism that involves a conformational change in the ERa protein and is unrelated to its activity as an activator of NF-jB. It is also consistent with the idea that IKKB may be a target of NSC35446.HCl for reversal of antiestrogen resistance.
About 70% of breast cancers are ERa-positive at presentation. Such cancers are candidates for first-line antiestrogen therapy, such as Tamoxifen [49] . However, about 50% of patients with advanced breast cancer who receive Tamoxifen fail to respond, despite ERa-positivity. Moreover, all patients with metastatic disease eventually develop Tamoxifen resistance [49] , and about 40% of patients with early-stage ERa-positive disease who receive Tamoxifen as an adjuvant relapse and die of disease [41] . In most cases of acquired antiestrogen resistance, breast cancers retain expression of ERa. Thus, patients with de novo or acquired antiestrogen resistance are candidates for novel approaches to target ERa. NSC35446.HCl, a specific ERa inhibitor that works by a distinct mechanism from Tamoxifen or Fulvestrant [12] and can target ERa signaling in antiestrogen-resistant cell lines such as LCC9 and T47DCO.
